Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People who have been diagnosed with a specific type of liver cancer called hepatocellular carcinoma (confirmed by biopsy or tissue sample, or by meeting standard clinical diagnosis guidelines), where curative treatments such as surgery, ablation, or radiotherapy are not an option
• People whose liver cancer has continued to grow or spread after receiving a first-line treatment combining targeted therapy and immunotherapy
• People whose doctors estimate they have a life expectancy of more than 3 months
• People who are largely able to carry out daily activities with little or no limitation (assessed using a standard medical scoring tool called the ECOG scale, scores 0 or 1)
• Women of childbearing age whose pregnancy blood test (taken within 7 days before the first dose) comes back negative; women of childbearing age and men whose partners could become pregnant must agree to use contraception from the time of signing the consent form until 24 weeks after the last dose of the study drug
• People whose recent blood test results meet specific minimum standards for blood cell counts, liver function, kidney function, and blood clotting, without having needed a blood transfusion or blood-stimulating medication in the 14 days before testing (confirm specific values with trial site)
• People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments

Who may not be able to join:

• People whose liver cancer has been confirmed by biopsy as a different subtype, such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or cholangiocarcinoma (bile duct cancer)
• People with more advanced liver damage, measured by a standard scoring system called Child-Pugh, where the score is 7 or higher
• People who have had a serious heart or cardiovascular problem in the 6 months before starting the trial, such as moderate-to-severe heart failure, unstable chest pain, a heart attack, a stroke, or a heart rhythm problem that affected blood flow; or people whose heart electrical test (ECG) shows a specific abnormality in a measurement called the QTc interval (above 480ms)
• People who have been diagnosed with another cancer within the past 5 years, with some exceptions including certain fully treated skin cancers, early-stage cervical cancer, localised prostate cancer after curative surgery, or early-stage breast cancer after curative surgery (hormone therapy for non-spreading prostate or breast cancer may still be permitted — confirm with trial site)
• People who have had an active autoimmune disease requiring whole-body (systemic) treatment in the past 2 years, such as autoimmune hepatitis or lupus
• People with an uncontrolled active infection, such as active tuberculosis or HIV; people with hepatitis B may be eligible if their virus levels are low and they are on stable antiviral medication (confirm with trial site)
• People who had major surgery in the 28 days before joining the trial, or who are expected to need major surgery during the study
• People who received a live vaccine in the 28 days before joining, or who are expected to need one during the study (a specific type of live flu vaccine is also restricted for a period before, during, and after treatment — confirm details with trial site)
• People who have taken part in another clinical trial or received an experimental drug within 4 weeks before signing the consent form
• People who have recently used higher-dose steroid medications (above 10mg per day of prednisone or equivalent) or other immune-suppressing medications within 14 days before the first dose, or immune-suppressing drugs within 1 week before starting; some exceptions apply for inhaled steroids, low-dose supplements, or short-term use for managing side effects such as nausea or allergic reactions (confirm with trial site)
• People with a known mental health condition, alcohol dependency, inability to stop smoking, or drug or substance misuse issues
• People who, in the treating doctor's judgment, have other factors that could make safe participation in the trial difficult, such as serious other illnesses, significant abnormalities in tests, or personal or social circumstances that could affect their safety or the collection of study data

Important: Always verify eligibility with the trial site directly before applying.